Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

ACET Interest Expense

Cost of servicing the company's debt during the period.

Adicet Bio, Inc.NASDAQ: ACET

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $23K, compared with $0 a year earlier. Trailing-twelve-month interest expense was $59K. Over 3 fiscal years it compounded at -23.4% a year.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest expense holds near $23K or moves back toward the trailing-twelve-month quarterly average of $14.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23K-4.2% QoQ
Last fiscal yearDec 2025
$36K+800.0% YoY
LTMMar 2026
$59K+2850.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+800.0%——
3-year CAGR-23.4%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
36K USD
Year-over-year change
+800.0%
4-year CAGR
-32.7%

Interest Expense vs competitors

How ACET compares with its peers on the latest reported figures

  • ACET's LTM Mar 2026 interest expense of $59K is the 5th highest of the 8 companies compared; the peer median is $904K.
  • Its year-over-year change of +2850.0% is the highest of 4, against a peer median of -10.3%.
  • Over three fiscal years its annual growth of -23.4% compares with a peer median of +10.2%.
ACET Competitors Peer median
Interest Expense for ACET and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$4.55M -10.3%—21.7%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.78M -17.6%+33.0%30.4%
ADAGAdagene Inc.LTM Jun 2024$974.16K —-12.6%119.4%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$904K +6.5%—39.4%
ACETAdicet Bio, Inc.LTM Mar 2026$59K +2850.0%-23.4%—
IMUXImmunic, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding ACET) $904K-10.3%+10.2%34.9%

Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.73M24.99M000
Cost of Revenue00006.38M
Gross Profit9.73M24.99M00(6.38M)
Gross Margin100.0%100.0%———
Research & Development48.94M71.25M106.04M99.32M99.13M
Selling, General & Admin22.22M26.3M26.53M28.29M22.99M
Operating Expenses71.16M97.54M152.04M127.62M115.73M
Depreciation & Amortization1.54M5.01M6.1M6.47M6.38M
EBITDA(60.41M)(64.7M)(136.54M)(110.65M)(110.39M)
EBITDA Margin-620.9%-258.9%———
Operating Income(61.43M)(72.55M)(152.04M)(127.62M)(122.11M)
Operating Margin-631.4%-290.3%———
Interest Income91K3.76M9.98M10.71M5.78M
Interest Expense176K80K25K4K36K
Other Income / Expenses(691K)2.76M9.38M10.49M5.31M
Income Before Tax(62.12M)(69.79M)(142.66M)(117.12M)(116.8M)
Pre-Tax Margin-638.5%-279.3%———
Income Tax Expense(125K)0000
Net Income(62M)(69.79M)(142.66M)(117.12M)(116.8M)
Net Margin-637.2%-279.3%———
EPS (Basic)(32.00)(27.20)(52.96)(21.28)(16.95)
EPS (Diluted)(32.00)(27.20)(52.96)(21.28)(16.95)
Weighted Avg Shares1.93M2.57M2.69M5.49M6.89M
Weighted Avg Shares (Diluted)1.93M2.57M2.69M5.49M6.89M

Adicet Bio, Inc.

NASDAQ:ACET

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.